Table 4.
$Can | Full approval | Conditional approval | Rejection | All |
---|---|---|---|---|
< $50,000 | 5 | 0 | 2 | 7 |
$50–100,000 | 6 | 5 | 2 | 13 |
$100–150,000 | 3 | 12 | 5 | 20 |
$150–200,000 | 0 | 14 | 8 | 22 |
> $200,000 | 0 | 23 | 7 | 30 |
Unreported | 1 | 1 | 0 | 2 |
All | 15 | 55 | 24 | 94 |
Chi-squared = 39.63, p < 0.001
ICER incremental cost-effectiveness ratio, pCODR pan-Canadian Oncology Drug Review